Medicare announces new payment rates for COVID-19 monoclonal antibody infusions
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.
Related News Articles
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…
Blog
Every pregnant woman deserves access to high-quality maternal care — from conception through postpartum. Yet in parts of the country, some of that care is…
Headline
The Centers for Medicare & Medicaid Services has released additional details on the application process for the Rural Health Transformation Program. CMS…
Headline
The AHA Aug. 28 expressed support for the Preserving Patient Access to Accountable Care Act in comments to House and Senate sponsors of the bill. The…